Australia markets closed

Viridian Therapeutics, Inc. (VRDN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
17.510.00 (0.00%)
At close: 04:00PM EDT
17.80 +0.29 (+1.66%)
After hours: 05:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close17.51
Open17.67
Bid17.48 x 400
Ask17.53 x 100
Day's range17.21 - 17.86
52-week range10.93 - 30.30
Volume940,111
Avg. volume983,359
Market cap1.099B
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., March 06, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 62,000 shares of the company’s common stock to two

  • Business Wire

    Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

    WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.

  • Business Wire

    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

    WALTHAM, Mass., February 27, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.